A number of TTK and PLK1 inhibitors have entered clinical development for the treatment of cancer, with the TTK inhibitors mainly explored in combination with taxanes and more recently with estrogen receptor (ER) antagonists (17). This evidence concerns the gene PLK1 and cancer.